Market turmoil forces Visx profit warning:
This article was originally published in Clinica
Executive Summary
Ophthalmic laser company Visx warned that its fourth-quarter results will be below estimates, causing the share price to plummet 26% to $9.3. The company says earnings per share will be between $0.15 and $0.17, compared with an analyst consensus of $0.20. Visx attributes the poor results to customer confusion over the range of procedure prices offered, as well as weak economic conditions. The company is also raising its reserves against customer receivables, as it believes that some of its customers may be unable to meet payments because of turmoil in the laser vision correction industry.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.